The acquisition centers on Centessa’s pipeline of orexin receptor 2 agonists, including lead candidate cleminorexton, targeted for narcolepsy and idiopathic hypersomnia.
Centessa plans to advance the orexin receptor 2 agonist into phase 2 studies for narcolepsy and idiopathic hypersomnia in late 2024.
“While prevailing treatment approaches only address the symptoms associated with narcolepsy type 1, we believe orexin agonists offer a disruptive approach, with the capacity to address the underlying pathology of the disorder."
Centessa Pharmaceuticals reported second-quarter highlights, spotlighting progress for ORX750, an oral selective orexin-2 receptor agonist in development for narcolepsy and other sleep disorders.
Read More